ArticleHaematologica2024

Asciminib stands out as the superior tyrosine kinase inhibitor to combine with anti-CD20 monoclonal antibodies for the treatment of CD20

Krzysztof Domka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.